Traeger et al., "Quality of life and mood predict posttraumatic stress disorder after
hematopoietic stem cell transplantation," Cancer, vol.
Douay et al., "Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic
hematopoietic stem cell transplantation," Blood, vol.
Nonmyeloablative
hematopoietic stem cell transplantation for systemic lupus erythematosus.
Autologous
hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: Still not out of fashion.
Berglund et al., "Improved survival after allogeneic
hematopoietic stem cell transplantation in recent years: a single-center study," Biology of Blood and Marrow Transplantation, vol.
Blood and marrow transplant clinical network toxicity consensus summary: thrombotic microangiopathy after
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571-5.
Use of G-CSF-stimulated marrow in allogeneic
hematopoietic stem cell transplantation settings: A comprehensive review.
Scieux et al., "Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic
hematopoietic stem cell transplantation," The Journal of Infectious Diseases, vol.
"The preclinical and clinical data obtained to date suggest that ProHema may address several of the unmet medical needs in the evolving field of
hematopoietic stem cell transplantation," said Steven Devine, M.D., professor of medicine and program director of the Blood and Marrow Transplant Program at the Ohio State University and a principal investigator of the Phase 2 clinical study.
Autologous CD34-selected
hematopoietic stem cell transplantation (HCST) can be safely and effectively performed in rheumatoid arthritis (RA), but the procedure is not curative,Australian researchers reported.
- US-based biopharmaceutical company CytoSen Therapeutics has received a favourable response from the US Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical
hematopoietic stem cell transplantation, the company said.
Omeros Corporation announced that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion recommending orphan drug designation of OMS721 for treatment in
hematopoietic stem cell transplantation. OMS721 is Omeros' lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway of the complement system.